Clinical trials in Slupsk

45 clinical trials in Slupsk, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Slupsk at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

45 trials in Slupsk

Open in trial search

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Idelalisib
Sponsor:Dizal Pharmaceutical Co. Ltd.

Contact Research Centre

Immune thrombocytopenia

Recruiting

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hormone receptor positive breast cancer+1

Recruiting

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Topotecan
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Shanghai Henlius Biotech Inc.

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

Registered drugNo placebo

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Follicular lymphoma

Recruiting

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Epizyme Inc.

Contact Research Centre

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Navtemadlin
Sponsor:Kartos Therapeutics Inc.

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Slupsk

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on blood cancers and solid tumors, including groundbreaking studies in multiple myeloma, lymphomas, and leukemia treatments.

Multiple Myeloma Studies
Lymphoma Research
Chronic Lymphocytic Leukemia

Novel combination therapies and targeted treatments are being evaluated for improved patient outcomes.

02 Respiratory Medicine

Clinical investigations targeting chronic respiratory conditions, with emphasis on developing enhanced treatment options for asthma and COPD management.

Asthma Control Studies
COPD Management
Inhaler Therapy Research

Focus on improving lung function and reducing exacerbations in respiratory disorders.

03 Cardiovascular Health

Research exploring the intersection of heart failure and mental health, investigating new approaches to treating complex cardiovascular conditions.

Heart Failure Studies
Depression in Cardiac Patients
Endothelial Function Research

Investigating the relationship between psychological well-being and cardiac outcomes.

Back to Poland All countries